208 related articles for article (PubMed ID: 2876744)
41. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.
van der Horst-Bruinsma IE; Clegg DO; Dijkmans BA
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S67-70. PubMed ID: 12463451
[TBL] [Abstract][Full Text] [Related]
42. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.
Neumann VC; Grindulis KA; Hubball S; McConkey B; Wright V
Br Med J (Clin Res Ed); 1983 Oct; 287(6399):1099-102. PubMed ID: 6138116
[TBL] [Abstract][Full Text] [Related]
43. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis.
Huang JL; Hung IJ; Hsieh KH
Asian Pac J Allergy Immunol; 1997 Jun; 15(2):71-5. PubMed ID: 9346269
[TBL] [Abstract][Full Text] [Related]
44. [New and old therapeutic options in ankylosing spondylitis--is there an indication for sulfasalazine?].
Braun J; Sieper J
Z Rheumatol; 2002 Apr; 61(2):151-8. PubMed ID: 12056292
[No Abstract] [Full Text] [Related]
45. Treatment of psoriatic arthritis with sulphasalazine: a one year open study.
Farr M; Kitas GD; Waterhouse L; Jubb R; Felix-Davies D; Bacon PA
Clin Rheumatol; 1988 Sep; 7(3):372-7. PubMed ID: 2906579
[TBL] [Abstract][Full Text] [Related]
46. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
47. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
[TBL] [Abstract][Full Text] [Related]
48. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
Huang F; Zhang J; Zheng Y; Xu JH; Li XF; Wu HX; Chen ZW; Zhao Z; Zhang YM
Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1043-7. PubMed ID: 22333175
[TBL] [Abstract][Full Text] [Related]
49. Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial.
Wang Y; Xiao X
Med Sci Monit; 2018 May; 24():2912-2918. PubMed ID: 29735967
[TBL] [Abstract][Full Text] [Related]
50. Sulphasalazine-induced systemic lupus erythematous in a patient with ankylosing spondylitis.
Tsai WC; Chen CJ; Yen JH; Liu HW
Clin Rheumatol; 2002 Aug; 21(4):339-40. PubMed ID: 12296286
[No Abstract] [Full Text] [Related]
51. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement.
Braun J; Pavelka K; Ramos-Remus C; Dimic A; Vlahos B; Freundlich B; Koenig AS
J Rheumatol; 2012 Apr; 39(4):836-40. PubMed ID: 22337244
[TBL] [Abstract][Full Text] [Related]
52. Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.
Feltelius N; Gudmundsson S; Wennersten L; Sjöberg O; Hällgren R; Klareskog L
Ann Rheum Dis; 1991 Jun; 50(6):369-71. PubMed ID: 1676256
[TBL] [Abstract][Full Text] [Related]
53. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis.
Wasner C; Britton MC; Kraines RG; Kaye RL; Bobrove AM; Fries JF
JAMA; 1981 Nov; 246(19):2168-72. PubMed ID: 7026817
[TBL] [Abstract][Full Text] [Related]
54. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.
Dougados M; vam der Linden S; Leirisalo-Repo M; Huitfeldt B; Juhlin R; Veys E; Zeidler H; Kvien TK; Olivieri I; Dijkmans B
Arthritis Rheum; 1995 May; 38(5):618-27. PubMed ID: 7748217
[TBL] [Abstract][Full Text] [Related]
55. Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial.
Steven MM; Morrison M; Sturrock RD
J Rheumatol; 1985 Aug; 12(4):735-7. PubMed ID: 3903158
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Gossec L; van der Heijde D; Melian A; Krupa DA; James MK; Cavanaugh PF; Reicin AS; Dougados M
Ann Rheum Dis; 2005 Nov; 64(11):1563-7. PubMed ID: 15731291
[TBL] [Abstract][Full Text] [Related]
57. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease.
Laasila K; Leirisalo-Repo M
Scand J Rheumatol; 1994; 23(6):338-40. PubMed ID: 7801059
[TBL] [Abstract][Full Text] [Related]
58. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
Tam HW; Yeo KJ; Leong PY; Chen CH; Li YC; Ma CM; Wang YH; Chiou JY; Wei JC
Int J Rheum Dis; 2017 Mar; 20(3):363-370. PubMed ID: 27943609
[TBL] [Abstract][Full Text] [Related]
59. Should tests for proteinuria be included in the monitoring schedule of sulphasalazine?
Helliwell PS
Br J Rheumatol; 1995 Aug; 34(8):790-1. PubMed ID: 7551669
[TBL] [Abstract][Full Text] [Related]
60. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: comment on the article by Clegg et al.
Helliwell PS
Arthritis Rheum; 1997 Oct; 40(10):1911-2. PubMed ID: 9336437
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
